Compound (I) Dosing for Alopecia Areata Across Renal Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Alopecia areata, an immune-mediated hair loss disorder, lacks effective treatment options, leading to significant psychological impact and limited therapeutic choices for affected individuals.
Innovation Solution
Administering 16 mg/day or 24 mg/day of Compound (I) or its pharmaceutically acceptable salt, with specific deuterium incorporation, to subjects with varying renal function and health conditions, monitored through eGFR, CBC, and symptom scales, to achieve significant reductions in SALT score and improved patient-reported outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Compound (I) is administered to treat alopecia areata, then hair regrowth is achieved, but safety concerns arise in subjects with renal impairment
Solution Approach 1:
The patent applies parameter changes by adjusting the dosage of Compound (I) based on the subject's renal function status. Specifically, subjects with moderate renal impairment (eGFR 30-59 mL/min) receive a reduced dosage compared to subjects with normal renal function. This dosage adjustment resolves the contradiction by maintaining treatment effectiveness while ensuring safety in subjects with compromised renal function.
2Adaptability or versatility
If Compound (I) is administered to subjects with renal impairment, then treatment coverage is expanded, but adverse effects may increase
Solution Approach 1:
The patent applies local quality by implementing differentiated treatment protocols for different renal function groups. Subjects with normal renal function receive standard dosing, while those with mild, moderate, or severe renal impairment receive progressively reduced dosages. This localized approach to dosage selection expands treatment coverage to include renal impairment patients while minimizing adverse effects through appropriate dose reduction for each specific renal function level.
3Object-affected harmful factors
If monitoring protocols are implemented for renal function and blood counts, then patient safety is improved, but treatment complexity increases
Solution Approach 1:
The patent applies preliminary action by requiring baseline assessment of renal function (eGFR) and complete blood count before initiating treatment with Compound (I). This pre-treatment monitoring allows clinicians to identify subjects with renal impairment and adjust dosing accordingly before adverse effects can occur. The baseline assessment establishes a reference point for future monitoring, improving patient safety while maintaining a manageable treatment protocol through standardized initial evaluation.
Data Source
AI summary
The disclosure relates to treatment of Alopecia Areata comprising the administration of Compound (I) or a pharmaceutically acceptable salt thereof.